| |
Newsroom /
Health and Fitness
/
Healthcare
/
Non-Hodgkin’s Lymphoma – Drug Pipeline Analysis and Market Forecasts to 2015
Non-Hodgkin’s Lymphoma – Drug Pipeline Analysis and Market Forecasts to 2015
Non-Hodgkin’s Lymphoma Therapeutics Market is Forecast to Show High Growth Rate, by Doubling in Size by 2015
Hyderabad,
AP,
India
(prbd.net)
04/02/2010
"Non-Hodgkin’s Lymphoma "
GlobalData estimated the global Non-Hodgkin’s Lymphoma (NHL) market to be worth $6.1 billion in 2008. It is forecast to grow at a compound annual growth rate (CAGR) of 11.1% annually over the next seven years to reach $12.8 billion by 2015. This growth can be primarily attributed to increased competition among the existing products, the release of new and enhanced treatment options, and the development of safer and more efficacious therapies. The NHL market growth will be further supported by the increased uptake of chemotherapy regimens, monoclonal antibodies and biologics. In 2008, Genentech Inc. (Roche), with its key drug Rituxan, was the leading player in the global NHL market.
The leading companies in the global NHL market are Genentech, Inc. (Roche), GlaxoSmithKline plc. (GSK), Immunomedics, Inc., Allos Therapeutics, Inc., Seattle Genetics, Inc., Eli Lilly and Company, Pfizer Inc./Wyeth, Novartis AG, Biogen Idec, and Genzyme Corporation. Together these companies accounted for more than 99% of the global market in 2008. Genentech, Inc. (Roche), with its blockbuster drug Rituxan, was the market leader with a share of more than 80%. However, companies such as Genentech, Inc. (Roche), GSK, Immunomedics, Inc., Allos Therapeutics, Inc., Seattle Genetics, Inc., Eli Lilly and Company, Biogen Idec, Genzyme Corporation, Therapeutics, Inc., Novartis AG, and Pfizer Inc./Wyeth have the most technologically advanced products in their pipeline portfolios and are expected to attract the most of investors’ attention. The global NHL market has seen some intense competition in recent times, which is expected to further intensify in the coming years.
GlobalData analysis has found that the current competition in the NHL market is strong and that the available treatment options have been fairly successful in meeting the market demand. The products currently available in the market have disease modifying properties and show a moderate disease progression free survival. However, the currently marketed products do not have a high safety profile and lack curative properties; this creates a potential market for new entrants with better efficacy and safety profiles. Currently, the NHL therapeutic landscape needs products which can offer a better safety profile have disease modifying properties, a faster onset of action and a longer duration of action. The extent of unmet needs in the NHL market is considered to be at a medium level and can be fulfilled by the technologically advanced products that are currently in the NHL pipeline.
GlobalData, the industry analysis specialist, has released its latest research, “Non-Hodgkin’s Lymphoma (NHL) – Drug Pipeline Analysis and Market Forecasts to 2015” that provides key data, information and analysis on the NHL market. The report provides a comprehensive overview on the annualized market data from 2000 to 2008, forecast forward to seven years till 2015. Report directs towards various concepts that relates to NHL market. Data in the report is incorporated with compilation of primary research and secondary research. Concepts included in the report are market characterization, opportunities and unmet needs associated with NHL drugs, competitive assessment, product profiles of major marketed products and promising drugs from pipeline, an overview on the discontinued projects, tables for NHL pipeline drugs that are in various development stages, pipeline by therapeutic class, implications for future market competition, key future players for NHL market.
visit our report store: http://www.globaldata.com/reportstore
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|